Any feedback?
Literature summary for 3.4.21.110 extracted from
- Human immunogenicity studies on group A streptococcal C5a peptidase (SCPA) as a potential vaccine against group A streptococcal infections (2004), Indian J. Med. Res., 119 Suppl, 95-98.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | SCPA is highly immunogenic in children infected with group A streptococcal pharyngitis | Streptococcus sp. |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| anti-ScpA antibody | rise in convalescent anti-SCPA antibody in all children aged 2-12 years, mean convalescent anti-SCPA antibody level is twice the level of mean actue anti-SCPA antibody, which is statistically significant | Streptococcus sp. |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Streptococcus sp. | - |
group A streptococcus | - |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| SCPA | - |
Streptococcus sp. |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
